IGHE and asthma: In addition, although the IgE level after 4 weeks of treatment was not confirmed to be valuable in predicting omalizumab treatment in children with moderate-to-severe asthma, 4-week IgE/baseline IgE ratio was partially useful in predicting efficacy.